Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Urology
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Infectious Disease
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
Related Questions
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
What is your approach to work up for patients referred for early onset osteoarthritis?
Do you find HZV titers useful in diagnosing shingles sine herpete?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
